C
Christopher Schaber
Publications - 7
Citations - 357
Christopher Schaber is an academic researcher. The author has contributed to research in topics: Lucinactant & Bronchopulmonary dysplasia. The author has an hindex of 3, co-authored 6 publications receiving 345 citations.
Papers
More filters
Journal ArticleDOI
A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
Sunil K. Sinha,Sunil K. Sinha,Thierry Lacaze-Masmonteil,Adolf Valls i Soler,Thomas E. Wiswell,Janusz Gadzinowski,Júlia Hajdú,Graham Bernstein,Manuel Sánchez-Luna,Robert Segal,Christopher Schaber,Joseph M. Massaro,Ralph B. D'Agostino +12 more
TL;DR: Lucinactant and poractant alfa were similar in terms of efficacy and safety when used for the prevention and treatment of RDS among preterm infants, with the lower boundary of the 95% CI for the difference being greater than the prespecified noninferiority margin.
Journal ArticleDOI
A Multicenter, Randomized, Masked, Comparison Trial of Lucinactant, Colfosceril Palmitate, and Beractant for the Prevention of Respiratory Distress Syndrome Among Very Preterm Infants
Fernando Moya,Janusz Gadzinowski,Eduardo Bancalari,Vicente Salinas,Benjamin Kopelman,Aldo Bancalari,Maria K Kornacka,T. Allen Merritt,Robert Segal,Christopher Schaber,Huei Tsai,Joseph M. Massaro,Ralph B. D'Agostino +12 more
TL;DR: It is concluded that lucinactant, the first of a new class of surfactants containing a functional protein analog of SP-B, is an effective therapeutic option for preterm infants at risk for RDS.
Patent
Surfactant treatment regimen
TL;DR: In this paper, the therapeutic or prophylactic administration of pulmonary surfactant to infants exhibiting or at risk of developing bronchopulmonary dysplasia is disclosed.
Journal ArticleDOI
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.
Ellen J. Kim,Aaron R. Mangold,Jennifer DeSimone,Henry K. Wong,Lucia Seminario-Vidal,Joan Guitart,James Appel,Larisa J. Geskin,E. Lakin,Neil J. Korman,Nathalie C. Zeitouni,Neda Nikbakht,K W Dawes,Oleg E. Akilov,Joi B. Carter,Michiyo Shinohara,Timothy M. Kuzel,Warren W. Piette,Neal Bhatia,Amy Musiek,David M. Pariser,Youn H. Kim,Dirk M. Elston,Erin E. Boh,Madeleine Duvic,Auris Huen,Theresa R. Pacheco,Jeffrey P. Zwerner,S. T. Lee,Michael Girardi,Christiane Querfeld,Kimberly A Bohjanen,Elise A. Olsen,Gary S. Wood,A. Rumage,Oreola Donini,Andrea M. Haulenbeek,Christopher Schaber,Richard C. Straube,C. Pullion,Alain H. Rook,Brian Poligone +41 more
TL;DR: The findings of this randomized clinical trial indicate that synthetic hypericin PDT is effective in early-stage patch and plaque MF/CTCL and has a favorable safety profile.
Patent
Surfactant treatment regimen for treating or preventing bronchopulmonary dysplasia
TL;DR: In this article, the therapeutic or prophylactic administration of pulmonary surfactant to infants exhibiting or at risk of developing bronchopulmonary dysplasia is disclosed.